Current anti-meningococcal vaccines are prepared from capsular saccharides (plain or conjugate). They target four serogroups A, C, Y and W135. No vaccine is available against serogroup B saccharide. However, protein-based vaccines (recombinant vaccines or outer membrane vesicle vaccines) allow developing vaccines against serogroup B isolates.